Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 15/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359048 | 0.86 | CCR5 (0.69) | CCR5KMT2AKCNH2 | |
| SCHEMBL16625302 | 0.84 | CCR5 (0.51) | CCR5KMT2AKCNH2GPR119 | |
| SCHEMBL3048764 | 0.84 | CCR5 (0.71) | CCR5KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL3035507 | 0.83 | CCR5 (0.70) | CCR5KMT2AKCNH2 | |
| SCHEMBL3579226 | 0.82 | CCR5 (0.69) | CCR5KMT2AKCNH2 | |
| SCHEMBL3048697 | 0.80 | CCR5 (0.70) | CCR5KMT2AKCNH2GPR119 | |
| SCHEMBL1164100 | 0.78 | MCHR1 (0.50) | CCR5 | |
| SCHEMBL2915480 | 0.76 | CCR5 (0.69) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL2912735 | 0.76 | CCR5 (0.67) | CCR5KCNH2 | |
| SCHEMBL6614913 | 0.75 | KDM4E (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008077885-A2 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | CCR5 1629/4885KMT2A 3248/4885KCNH2 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.